SCHEDULE 13G/A: PRIMECAP Management Discloses 9.15% Stake in Rhythm Pharmaceuticals

PRIMECAP Management Co./CA/ has filed an amended Schedule 13G, reporting a 9.15% beneficial ownership stake in Rhythm Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• PRIMECAP MANAGEMENT CO/CA/ has filed an Amendment No. 9 to Schedule 13G, disclosing its beneficial ownership in Rhythm Pharmaceuticals, Inc.
• As of March 31, 2025, PRIMECAP MANAGEMENT CO/CA/ beneficially owns 5,787,322 shares of Rhythm Pharmaceuticals, Inc. common stock.
• This ownership stake represents 9.15% of the total outstanding common stock of Rhythm Pharmaceuticals, Inc.
• PRIMECAP MANAGEMENT CO/CA/ holds sole voting power and sole dispositive power over all 5,787,322 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• PRIMECAP Odyssey Aggressive Growth Fund is specifically identified as having an interest exceeding five percent of the total outstanding common stock of Rhythm Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant and continued institutional investment in Rhythm Pharmaceuticals, Inc. by PRIMECAP MANAGEMENT CO/CA/, which can be viewed as a positive signal of investor confidence. However, as an amendment, it primarily updates an existing position rather than signaling a new, major event.

Positives

• The disclosure of a significant 9.15% stake held by an institutional investment adviser (PRIMECAP MANAGEMENT CO/CA/) indicates continued confidence in Rhythm Pharmaceuticals, Inc.
• The certification that the holding is for investment purposes in the ordinary course of business suggests a long-term, non-activist position by a major investor.

Future Outlook

This document, a Schedule 13G filing, pertains solely to beneficial ownership disclosure by an investment adviser and does not contain any forward-looking statements or guidance from Rhythm Pharmaceuticals, Inc. regarding its operations or financial performance.

Industry Context

This filing is a routine regulatory disclosure of a significant ownership stake by an institutional investor in a publicly traded pharmaceutical company. It does not provide broader industry trends, competitive analysis, or specific insights into the pharmaceutical sector beyond the ownership structure of Rhythm Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like PRIMECAP MANAGEMENT CO/CA/ may provide a degree of confidence or stability, as it indicates a large, long-term investment in the company.

Key Dates

Keywords

Rhythm Pharmaceuticals, PRIMECAP Management, Schedule 13G, beneficial ownership, institutional investment, common stock, 76243J105